Positive results from Echo Therapeutics' Symphony tCGM System study

Study Demonstrates Improvement of Accuracy with New Biosensor

Echo Therapeutics, Inc. (OTC Bulletin Board: ECTE), a company developing its needle-free Symphony(TM) tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelude(TM) SkinPrep System for transdermal drug delivery, today announced positive results of a clinical study of its Symphony tCGM System in patients with Type 1 and Type 2 Diabetes. Echo's non-invasive Symphony tCGM System consists of its wireless transmission and transdermal biosensor technologies and its Prelude SkinPrep System, which incorporates leading-edge, needle-free, controlled skin ablation. Echo's Symphony tCGM System is designed to provide patients with diabetes and critical care patients with a reliable, affordable, and easy-to-use, needle-free continuous glucose monitoring device. The purpose of the study was to test the performance of its new, improved one-piece, cost-effective and easy-to-use biosensor.

"This study represents another major step forward in our Symphony development program," stated Patrick Mooney, M.D., Echo's Chairman and CEO. "We believe that we have successfully developed a new cost-effective, one-piece biosensor and, with this study, we have demonstrated improvement in the accuracy of our Symphony system glucose readings. Data from this study demonstrates that Symphony, using the new, improved, cost-effective biosensor, is safe, accurate and reliable at monitoring glucose levels. We look forward to continued progress with our Symphony development program throughout this year and next as we move toward our goal of making Symphony available to patients."

SOURCE Echo Therapeutics, Inc.